GSA Capital Partners LLP Increases Stock Position in STAAR Surgical (NASDAQ:STAA)

GSA Capital Partners LLP lifted its position in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 134.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 118,789 shares of the medical instruments supplier's stock after buying an additional 68,196 shares during the period. STAAR Surgical comprises 0.3% of GSA Capital Partners LLP's investment portfolio, making the stock its 6th largest position. GSA Capital Partners LLP owned 0.24% of STAAR Surgical worth $4,413,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Van ECK Associates Corp increased its stake in shares of STAAR Surgical by 12.7% in the third quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier's stock worth $129,000 after buying an additional 393 shares during the period. Sei Investments Co. boosted its position in shares of STAAR Surgical by 2.7% during the second quarter. Sei Investments Co. now owns 15,087 shares of the medical instruments supplier's stock valued at $718,000 after purchasing an additional 394 shares in the last quarter. Texas Permanent School Fund Corp grew its stake in STAAR Surgical by 1.0% in the first quarter. Texas Permanent School Fund Corp now owns 42,577 shares of the medical instruments supplier's stock worth $1,630,000 after purchasing an additional 407 shares during the period. Creative Planning raised its holdings in STAAR Surgical by 8.0% in the third quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier's stock worth $205,000 after purchasing an additional 408 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in STAAR Surgical by 3.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,343 shares of the medical instruments supplier's stock valued at $540,000 after buying an additional 418 shares during the period. Institutional investors own 96.70% of the company's stock.

STAAR Surgical Price Performance

Shares of STAAR Surgical stock traded down $1.40 during trading on Tuesday, hitting $29.02. 534,139 shares of the company's stock traded hands, compared to its average volume of 715,602. The business has a 50-day simple moving average of $31.59 and a 200-day simple moving average of $37.75. The stock has a market capitalization of $1.43 billion, a P/E ratio of 69.14 and a beta of 0.61. STAAR Surgical has a 1 year low of $26.66 and a 1 year high of $52.68.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on STAA. Stifel Nicolaus decreased their price target on shares of STAAR Surgical from $50.00 to $44.00 and set a "buy" rating for the company in a research note on Monday, August 26th. Needham & Company LLC reiterated a "hold" rating on shares of STAAR Surgical in a report on Thursday, October 31st. BTIG Research upped their price target on STAAR Surgical from $46.00 to $53.00 and gave the stock a "buy" rating in a research note on Monday, July 15th. Morgan Stanley cut STAAR Surgical from an "equal weight" rating to an "underweight" rating and lowered their price objective for the company from $50.00 to $37.00 in a research note on Monday, July 15th. Finally, Canaccord Genuity Group cut their target price on STAAR Surgical from $41.00 to $31.00 and set a "hold" rating on the stock in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, STAAR Surgical has a consensus rating of "Hold" and a consensus target price of $43.33.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.